Stockreport

Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024

Exact Sciences Corporation  (EXAS) 
Last exact sciences corporation earnings: 2/11 04:05 pm Check Earnings Report
PDF Data presented show sensitivities of 88% for colorectal cancer and 31% for advanced precancerous lesions at 90% specificityScientific insights reflect Exact Sciences’ co [Read more]